Praxis: Strong Buy As Relutrigine Submission Accepted Plus Expansion Potential

Terry ChrisomalisInvesting Group LeaderFollow5ShareSavePlay(17min)Comment(1)SummaryPraxis Precision Medicines, Inc. remains a Strong Buy, driven by two NDA submissions and pipeline expansion opportunities targeting essential tremor and developmental and epileptic encephalopathies.The company's relutrigine achieved a 46% placebo-adjusted reduction in motor seizure frequency for SCN2A/SCN8A DEE and is under FDA priority review with a PDUFA date of September 27, 2026.Pipeline expansion includes relutrigine's potential sNDA for broad DEE and elsunersen for early-onset SCN2A DEE, with key data readouts expected in 2026–2027.With $926.1M cash at 2025 year-end and a $621.2M January 2026 raise, PRAX is funded into 2028, supporting robust R&D and regulatory milestones.Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Tashi-Delek/E+ via Getty Images The last time I spoke about Praxis Precision Medicines, Inc. (PRAX), it was in a Seeking Alpha article entitled "Praxis: Moving To Strong Buy Based On Ulixacaltamide Success In Treating ETThis article was written byTerry Chrisomalis14.8K FollowersFollowTerry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare. He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.